Strategic Initiative

Slingshot members are tracking this corporate initiative:

Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases for $1.2B

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
GILD Community voting in process
Nimbus Therapeutics Community voting in process
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Apr 04, 2016
Projected Implementation:
Q1, 2016
Relevance Tracked Until:
Q2, 2016
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Acetyl-coa Carboxlyase, Acc, Nash, Liver Diseases, Ndi-010976, Fast Track Designation, Metabolic Dysfunction, Hepatocellular Injury, Acc Inhibitors, Aberrant Lipid-derived Signaling, Steatosis, Fibrosis, Inflammation